Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11570250 | PMC |
| http://dx.doi.org/10.22575/interventionalradiology.2024-0028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preface to the Featured Topic "Image-guided Puncture".
Interv Radiol (Higashimatsuyama)
November 2024
Department of Interventional Radiology, Miyakojima IGRT Clinic, Japan.
[Preface for special issue on Microbial Chemical Factories].
Sheng Wu Gong Cheng Xue Bao
August 2024
College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310014, Zhejiang, China.
Microbial chemical factories utilize engineering design principles to re-build natural production pathways, enabling the precise, quantitative, and efficient synthesis of chemicals. This is achieved through the optimization of synthetic pathways, the reconstruction of biochemical networks, the development of novel components, and the integration of pathways with cellular and environmental contexts. As a transformative approach to chemical production, microbial chemical factories play a critical role in establishing renewable raw material pathways for industrial economic development and advancing sustainable growth.
View Article and Find Full Text PDFPreface for special issue: "Emerging strategies, technologies, and approaches for the next generation ADCs".
Xenobiotica
August 2024
BioAnalytical Sciences, Genentech Inc, South San Francisco, CA, USA.
1. Antibody-drug conjugates (ADCs) represent an advanced category of biotherapeutic agents, typically consisting of an antibody bound to a biologically-active cytotoxic agent. Since the first ADC, Mylotarg, was approved in 2000, there have been fifteen ADCs sanctioned to date, with thirteen receiving approval from the FDA for the treatment of a variety of cancers, including blood malignancies and solid tumors.
View Article and Find Full Text PDFAging and neurodegeneration: From molecular mechanisms to therapeutic interventions.
J Neurochem
August 2024
Institute for Basic Health Sciences, Department of Biochemistry, Federal University of Rio Grande Do Sul, Porto Alegre, Brazil.
Protein aggregation is a common age-associated process and can be a pathological hallmark of various neurodegenerative conditions, possibly because of an age-associated decline in the activity of components of the proteostasis network. The specific molecular drivers of protein aggregation in certain cell types are not well understood, posing tremendous challenges to current research aimed at devising strategies to treat neurodegenerative diseases. This preface introduces the special issue "Aging and Neurodegeneration: from molecular mechanisms to therapeutic interventions," featuring articles that assess the drivers of pathology in the aging cell, including oxidative stress, protein glycation/aggregation, and mitochondrial impairment.
View Article and Find Full Text PDFMining and engineering activity in catalytic amyloids.
Methods Enzymol
May 2024
Interdisciplinary Nanoscience Center, Aarhus University, Aarhus, Denmark; Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark. Electronic address:
This chapter describes how to test different amyloid preparations for catalytic properties. We describe how to express, purify, prepare and test two types of pathological amyloid (tau and α-synuclein) and two functional amyloid proteins, namely CsgA from Escherichia coli and FapC from Pseudomonas. We therefore preface the methods section with an introduction to these two examples of functional amyloid and their remarkable structural and kinetic properties and high physical stability, which renders them very attractive for a range of nanotechnological designs, both for structural, medical and catalytic purposes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!